https://http%3a%2f%2fwww.omsul.ptRSS documenthttps://www.omsul.pt/noticias/nejm-bamlanivimab-plus-etesevimab-in-mild-or-moderate-covid-19Mon, 26 Jul 2021 09:19:00 GMThttps://www.omsul.pt/noticias/nejm-bamlanivimab-plus-etesevimab-in-mild-or-moderate-covid-19https://www.omsul.pt/noticias/bmj-effectiveness-of-the-pfizer-biontech-and-oxford-astrazeneca-vaccines-on-covid-19-related-symptoms-hospital-admissions-and-mortality-in-older-adults-in-england-test-negative-case-control-studyWed, 26 May 2021 09:26:00 GMThttps://www.omsul.pt/noticias/bmj-effectiveness-of-the-pfizer-biontech-and-oxford-astrazeneca-vaccines-on-covid-19-related-symptoms-hospital-admissions-and-mortality-in-older-adults-in-england-test-negative-case-control-studyhttps://www.omsul.pt/noticias/the-lancet-convalescent-plasma-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised-controlled-open-label-platform-trialWed, 26 May 2021 09:23:00 GMThttps://www.omsul.pt/noticias/the-lancet-convalescent-plasma-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised-controlled-open-label-platform-trialhttps://www.omsul.pt/noticias/jama-effect-of-intermediate-dose-vs-standard-dose-prophylactic-anticoagulation-on-thrombotic-events-extracorporeal-membrane-oxygenation-treatment-or-mortality-among-patients-with-covid-19-admittedFri, 26 Mar 2021 11:23:00 GMThttps://www.omsul.pt/noticias/jama-effect-of-intermediate-dose-vs-standard-dose-prophylactic-anticoagulation-on-thrombotic-events-extracorporeal-membrane-oxygenation-treatment-or-mortality-among-patients-with-covid-19-admittedhttps://www.omsul.pt/noticias/jama-association-of-convalescent-plasma-treatment-with-clinical-outcomes-in-patients-with-covid-19a-systematic-review-and-meta-analysisWed, 03 Mar 2021 10:41:00 GMThttps://www.omsul.pt/noticias/jama-association-of-convalescent-plasma-treatment-with-clinical-outcomes-in-patients-with-covid-19a-systematic-review-and-meta-analysishttps://www.omsul.pt/noticias/nejm-bnt162b2-mrna-covid-19-vaccine-in-a-nationwide-mass-vaccination-settingWed, 03 Mar 2021 10:39:00 GMThttps://www.omsul.pt/noticias/nejm-bnt162b2-mrna-covid-19-vaccine-in-a-nationwide-mass-vaccination-settinghttps://www.omsul.pt/noticias/bmj-early-initiation-of-prophylactic-anticoagulation-for-prevention-of-coronavirus-disease-2019-mortality-in-patients-admitted-to-hospital-in-the-united-states-cohort-studyWed, 17 Feb 2021 08:52:00 GMThttps://www.omsul.pt/noticias/bmj-early-initiation-of-prophylactic-anticoagulation-for-prevention-of-coronavirus-disease-2019-mortality-in-patients-admitted-to-hospital-in-the-united-states-cohort-studyhttps://www.omsul.pt/noticias/jama-association-of-intravenous-immunoglobulins-plus-methylprednisolone-vs-immunoglobulins-alone-with-course-of-fever-in-multisystem-inflammatory-syndrome-in-childrenMon, 15 Feb 2021 10:17:00 GMThttps://www.omsul.pt/noticias/jama-association-of-intravenous-immunoglobulins-plus-methylprednisolone-vs-immunoglobulins-alone-with-course-of-fever-in-multisystem-inflammatory-syndrome-in-childrenhttps://www.omsul.pt/noticias/bmj-effect-of-tocilizumab-on-clinical-outcomes-at-15-days-in-patients-with-severe-or-critical-coronavirus-disease-2019-randomised-controlled-trialTue, 09 Feb 2021 09:22:00 GMThttps://www.omsul.pt/noticias/bmj-effect-of-tocilizumab-on-clinical-outcomes-at-15-days-in-patients-with-severe-or-critical-coronavirus-disease-2019-randomised-controlled-trialhttps://www.omsul.pt/noticias/nejm-duration-of-culturable-sars-cov-2-in-hospitalized-patients-with-covid-19Tue, 09 Feb 2021 09:21:00 GMThttps://www.omsul.pt/noticias/nejm-duration-of-culturable-sars-cov-2-in-hospitalized-patients-with-covid-19